GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maxygen, Inc. (FRA:MYN) » Definitions » Cyclically Adjusted Price-to-FCF

Maxygen, (FRA:MYN) Cyclically Adjusted Price-to-FCF : (As of May. 05, 2024)


View and export this data going back to . Start your Free Trial

What is Maxygen, Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Maxygen, Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Maxygen,'s Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maxygen, Cyclically Adjusted Price-to-FCF Chart

Maxygen, Annual Data
Trend Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Maxygen, Quarterly Data
Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Maxygen,'s Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Maxygen,'s Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Maxygen,'s Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Maxygen,'s Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Maxygen,'s Cyclically Adjusted Price-to-FCF falls into.



Maxygen, Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Maxygen,'s Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2013 is calculated as:

For example, Maxygen,'s adjusted Free Cash Flow per Share data for the three months ended in Mar. 2013 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2013 (Change)*Current CPI (Mar. 2013)
=-0.041/98.2094*98.2094
=-0.041

Current CPI (Mar. 2013) = 98.2094.

Maxygen, Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
200306 -0.220 77.505 -0.279
200309 -0.168 78.138 -0.211
200312 -0.256 77.758 -0.323
200403 -0.172 79.066 -0.214
200406 -0.221 80.037 -0.271
200409 -0.182 80.121 -0.223
200412 -0.167 80.290 -0.204
200503 -0.308 81.555 -0.371
200506 -0.134 82.062 -0.160
200509 -0.221 83.876 -0.259
200512 -0.025 83.032 -0.030
200603 -0.184 84.298 -0.214
200606 -0.004 85.606 -0.005
200609 -0.221 85.606 -0.254
200612 -0.111 85.142 -0.128
200703 -0.214 86.640 -0.243
200706 -0.191 87.906 -0.213
200709 -0.224 87.964 -0.250
200712 -0.216 88.616 -0.239
200803 -0.227 90.090 -0.247
200806 -0.190 92.320 -0.202
200809 1.687 92.307 1.795
200812 -0.152 88.697 -0.168
200903 -0.174 89.744 -0.190
200906 0.034 91.003 0.037
200909 -0.174 91.120 -0.188
200912 -0.070 91.111 -0.075
201003 0.168 91.821 0.180
201006 -0.292 91.962 -0.312
201009 0.045 92.162 0.048
201012 -0.120 92.474 -0.127
201103 -0.046 94.283 -0.048
201106 -0.077 95.235 -0.079
201109 -0.023 95.727 -0.024
201112 0.007 95.213 0.007
201203 -0.074 96.783 -0.075
201206 0.822 96.819 0.834
201209 -0.044 97.633 -0.044
201212 0.023 96.871 0.023
201303 -0.041 98.209 -0.041

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Maxygen,  (FRA:MYN) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Maxygen, Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Maxygen,'s Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Maxygen, (FRA:MYN) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Website
Maxygen, Inc., is incorporated in Delaware. It is a biotechnology company. It discovers and develops improved next-generation protein pharmaceuticals for the treatment of disease and serious medical conditions. The Company's MAXY-G34 product candidate has been designed to be an improved next-generation pegylated, G-CSF for the treatment of chemotherapy-induced neutropenia. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The Company completed a Phase IIa clinical trial for its MAXY-G34 product candidate for the treatment of chemotherapy-induced neutropenia in breast cancer patients in which MAXY-G34 was safe and effective in reducing chemotherapy-induced neutropenia with no serious adverse events, drug-related grade 3 or 4 adverse events or immunogenicity reported in any patient receiving MAXY-G34. Adverse events were consistent with known side effects of G-CSF molecules. The Company is subject to regulation by the FDA and comparable regulatory agencies in foreign countries with respect to any development and commercialization of its MAXY-G34 product candidate or any other products it may acquire in the future.

Maxygen, (FRA:MYN) Headlines